Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea (ACS)

Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.

This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.

Study Overview

• Status: Recruiting
• Conditions: Dyspnea; Acute Coronary Syndromes; Ticagrelor
• Intervention / Treatment: Other: STANDART CARE; Other: STANDART CARE & FAN THERAPY

Detailed Description

Patients in the coronary intensive care unit receiving ticagrelor and meeting the inclusion criteria will be included. The study includes two groups: a control group receiving standard care and an experimental group receiving standard care plus hand fan therapy. A total of 110 participants (55 per group) will be recruited. Randomization will be performed using a computer-based randomization program. Due to the nature of the intervention and sample characteristics, participants and the researcher will not be blinded. Data will be analyzed by a statistician not involved in the study, and the findings will be reported.

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Emine Tuğba YORULMAZ, research assistant; Phone Number: +905556177281; Email: tugbayoorlmz@gmail.com
• Study Contact Backup: Name: Arzu ERKOÇ, Associate professor; Phone Number: +905552735500; Email: arzu.erkochut@iuc.edu.tr

Study Locations

• Turkey (Türkiye)
  • Avcılar
    • Istanbul, Avcılar, Turkey (Türkiye), 34320
      • Not yet recruiting
      • İstanbul Üniversitesi-Cerrahapaşa
  • Üsküdar
    • Istanbul, Üsküdar, Turkey (Türkiye), 34668
      • Recruiting
      • Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Between the ages of 18 and 65,
• No severe hearing and vision problems,
• Can speak and understand Turkish,
• Easy to communicate with,
• First-time sufferer of acute coronary syndrome (ACS) for the first time,
• Decided to start ticagrelor therapy,
• Able to adapt to treatment,
• Individuals who volunteered to participate in the research.

Exclusion Criteria:

• Having any problem that prevents you from communicating cognitively, emotionally and verbally,
• Obstructive sleep abnormalities,
• Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),
• With metabolic abnormalities,
• Intubated after the procedure,
• Previously treated with ticagrelor,
• Individuals who did not volunteer to participate in the study. Losses to follow up
• Individuals who wish to leave the study voluntarily.
• Saturation value below 95%,
• The one with the arrest,
• Who will not be able to fulfill the requirements of the work,
• Individuals with life-threatening conditions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Standard Care (Control Group); Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.	Other: STANDART CARE; Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.
Experimental: Standard Care + Fan Therapy (Experimental Group); In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of ~15 cm. Dyspnea severity and number of episodes will be recorded during this period. Device: Hand Fan	Other: STANDART CARE & FAN THERAPY; In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of ~15 cm. Dyspnea severity and number of episodes will be recorded during this period.; Other Names: Fan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of ticagrelor-associated dyspnea	The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded.	Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to onset of ticagrelor-associated dyspnea	The time interval between ticagrelor administration and the first reported dyspnea episode will be measured in minutes.	Time Frame: Within 120 minutes after ticagrelor administration (T1-T4) Unit of Measure: Minutes (min)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Severity of ticagrelor-associated dyspnea	Dyspnea severity will be assessed using the Modified Borg Dyspnea Scale (0-10) at T1 (baseline), T2 (30 min), T3 (60 min), and T4 (120 min) after ticagrelor administration. Higher scores indicate greater symptom severity.	Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Score (0-10)

Collaborators and Investigators

• Sponsor: Acibadem University

Study record dates

Study Major Dates

• Study Start (Actual): March 15, 2025
• Primary Completion (Estimated): January 10, 2026
• Study Completion (Estimated): January 30, 2026

Study Registration Dates

• First Submitted: June 18, 2025
• First Submitted That Met QC Criteria: December 4, 2025
• First Posted (Actual): December 8, 2025

Study Record Updates

• Last Update Posted (Actual): December 8, 2025
• Last Update Submitted That Met QC Criteria: December 4, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Ticagrelor; Nursing; Dyspnea; Non-pharmacological intervention; Hand fan therapy
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Heart Diseases; Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Myocardial Ischemia; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Dyspnea; Acute Coronary Syndrome; CCP110 protein, human
• Other Study ID Numbers: ATADEK2024-10/449; Is an identifier other (Other Identifier)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No